Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 receptor inhibitor has been
consistently shown to reduce recurrent major adverse cardiovascular events (MACE) in …

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the
cornerstone of pharmacologic management of patients with acute coronary syndrome (ACS) …

Platelets initiate the formation of a thrombus at the site of an arterial injury, and the clotting
cascade is activated as the thrombus matures. After coronary stent placement, dual …

Dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and an inhibitor of
the platelet P2Y12 receptor for ADP, remains among the most investigated treatments in …

Background: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention with drug-eluting stents remains uncertain. We compared short-term (< …

Dual antiplatelet therapy (DAPT) is the cornerstone of pharmacological treatment aimed at
preventing the atherothrombotic complications in patients with a variety of coronary artery …

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is currently
recommended for one year after coronary stent implantation or an episode of acute coronary …

Dual antiplatelet therapy (DAPT) is standard treatment for patients with acute coronary
syndromes (ACS), typically comprising the use of aspirin with either an irreversible …

Dual antiplatelet therapy (DAPT), the combination of aspirin (ASA), and a P2Y 12 inhibitor,
protects against stent thrombosis and new atherothrombotic events after a stent implantation …

Dual antiplatelet therapy (DAPT) prevents recurrent ischemic events after an acute coronary
syndrome (ACS) as well as stent thrombosis (ST) in patients with prior stent implantation …